The world of cosmetic surgery is one of the most challenging fields for contemporary medicine. Examined under that light the accomplishments of Jennifer Walden are much more amazing. That’s not to say the accomplishments aren’t amazing regardless of the light you cast them in. The work she accomplished during her time in Manhattan is nothing to scoff at. However, when you factor in how far she has managed to go as a woman in a field dominated by men her true brilliance is revealed. Despite all of the work she was involved in while living in Manhattan Dr.Walden decided to return to her hometown of Austin,TX.
While she would’ve liked to stay in Manhattan starting a family made returning home much more appealing. She wanted her twin sons to grow up around family and experience the culture she grew up with. Moving her practice to Texas was a difficult process, but with the help of her mother and nannies she has managed to make to relocate without any problems. In Austin she will practice cosmetic surgery at the esteemed Westlake Medical Center. Here she conducts surgeries right next to her private office and maintains the highest standards for her practice. The set up is perfect for juggling motherhood and work together.
When Walden decided it was time to return to Austin she did so with a certain philosophy in mind. She sets out to do what is in the best interest of her children and her patients. If there is anywhere she can improve and give more she doesn’t hesitate to work on making that change. Her years of experience give her insight into which decisions are the best for practice. With her long history of leadership in the cosmetic surgery profession she is better equipped than anyone else to understand exactly what she needs to do.
Clay Siegall is the face of Seattle Genetics and the force that has led to many of the Pharmaceutical Company’s groundbreaking achievements. He has come a long way in making Seattle Genetics what it is today and the future seems to be getting brighter.
Clay Siegall is a co-founder, CEO and President of Seattle Genetics, a Drug Research Center that is instrumental in the research and discovery of newer cancer treatment solutions. He is also the chairman of company’s Board of Directors, a keynote position that has helped him secure several grants to fund their cancer research projects.
Mr. Siegall is a passionate contributor to the cancer research community. He has dedicated an entire career to finding tangible solutions for the cure or alleviation of cancer cases, especially lymphoma patients. Before joining Seattle Genetics, Clay had a 6-year contract with the National Cancer Institute before moving to the National Institute of Health where he worked for 3 years. In this period, he studied cancer cases which were crucial in laying down a path for his journey to developing one of the most lucrative cancer treatment drug in the US and Canadian market right now.
Seattle Genetics is currently pushing their main drug, Adcetris. Adcetris is the Drug Center’s flagship drug that works as an alternative treatment for patients with advanced lymphoma. Seattle Genetics raked in an estimated $325milion on the premier of Adcetris, and is on the verge of making it an FDA-approved commercial drug for lymphoma treatment.
Mr. Siegall played the biggest role in Seattle Genetics’ headline achievement with Adcetris. As the Chairman of the pharmaceutical company’s board, he garnered over $1.2 billion in funds from both private and public investors drawn by the company’s IPO announcement in 2001. He then moved to seek licenses for the approval of Adcetris as a test drug for lymphoma. Under his guide, Seattle Genetics received the green light from major players in the field of health like Glaxo Smith Kline, Pfizer, Abbvie, and Genentech.
Currently, there is a possibility of Adcetris becoming commercially available as a lymphoma solution once their Echelon-1 trials on the drug are completed in 2017. This will definitely put Seattle Genetics on the global map, and Clay Siegall on the headlines as the crusader who made this achievement possible.